Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by MJP Associates Inc. ADV

MJP Associates Inc. ADV raised its stake in Edwards Lifesciences Co. (NYSE:EW) by 4.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,590 shares of the medical research company’s stock after buying an additional 340 shares during the period. MJP Associates Inc. ADV’s holdings in Edwards Lifesciences were worth $793,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Crewe Advisors LLC purchased a new stake in shares of Edwards Lifesciences during the first quarter valued at $28,000. Riverview Trust Co acquired a new stake in shares of Edwards Lifesciences during the first quarter valued at approximately $34,000. DSM Capital Partners LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $28,000. Webster Bank N. A. acquired a new position in Edwards Lifesciences in the 2nd quarter worth approximately $39,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new position in Edwards Lifesciences during the 4th quarter worth approximately $34,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. TD Cowen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their target price for the company from $100.00 to $70.00 in a report on Thursday, July 25th. Baird R W downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 25th. StockNews.com cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 25th. Daiwa Capital Markets raised shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Finally, Daiwa America upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a report on Wednesday, July 31st. Fourteen investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average price target of $82.10.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded up $1.35 during trading hours on Friday, hitting $64.64. 5,985,117 shares of the company’s stock were exchanged, compared to its average volume of 4,027,077. The company’s 50-day moving average price is $82.82 and its 200-day moving average price is $86.16. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The stock has a market capitalization of $38.95 billion, a price-to-earnings ratio of 27.86, a PEG ratio of 2.57 and a beta of 1.11. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. The company had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The business’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.66 EPS. On average, sell-side analysts expect that Edwards Lifesciences Co. will post 2.71 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 5,625 shares of the stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $90.45, for a total value of $508,781.25. Following the completion of the transaction, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,764,242.45. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $87.54, for a total value of $437,700.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $4,108,777.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 5,625 shares of the business’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $90.45, for a total value of $508,781.25. Following the completion of the transaction, the chief financial officer now directly owns 30,561 shares in the company, valued at approximately $2,764,242.45. The disclosure for this sale can be found here. Insiders have sold 24,242 shares of company stock worth $2,168,470 over the last 90 days. Corporate insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.